Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias

作者: Wai Cheng Foong , Jacqueline J Ho , C Khai Loh , Vip Viprakasit

DOI: 10.1002/14651858.CD011579.PUB2

关键词:

摘要: Background Non-transfusion dependent beta thalassaemia is a subset of inherited haemoglobin disorders characterised by reduced production the globin chain molecule leading to anaemia varying severity. Although blood transfusion not necessity for survival, it required when episodes chronic occur. This can impair growth and affect quality life. People with non-transfusion suffer from iron overload due their body's increased capability absorbing food sources. Iron becomes more pronounced in those requiring transfusion. higher foetal level have been found require fewer transfusions. Hydroxyurea has used increase level; however, its efficacy reducing transfusion, complications safety need be established. Objectives To assess effectiveness, appropriate dose regimen hydroxyurea people (haemoglobin E combined intermedia). Search methods We searched Cochrane Cystic Fibrosis Genetic Disorders Group's Haemoglobinopathies Trials Register, compiled electronic database searches handsearching relevant journals. also ongoing trials registries reference lists articles reviews.Date last search: 30 April 2016. Selection criteria Randomised or quasi-randomised controlled comparing placebo standard treatment different doses hydroxyurea. Data collection analysis Two authors independently applied inclusion order select inclusion. Both assessed risk bias extracted data. A third author verified these assessments. Main results No care were found. However, we included one randomised trial (n = 61) 20 mg/kg/day 10 24 weeks.Both levels lower at weeks mg group compared group, mean difference -2.39 (95% confidence interval - 2.8 -1.98) -1.5 -1.83 -1.17), respectively. Major adverse effects significantly common neutropenia ratio 9.93 1.34 73.97) thrombocytopenia 3.68 1.13 12.07). was reported minor (gastrointestinal disturbances raised liver enzymes). The effect on frequency reported.The overall outcomes graded as very low mainly because derived only small study an unclear method allocation concealment. Authors' conclusions There no evidence show whether any controls Administration resulted seems safer effects. It capable Large well-designed sufficient duration follow up are recommended.

参考文章(61)
Elisabeth Kohne, Enno Kleihauer, Hemoglobinopathies in Germany Deutsches Aerzteblatt Online. ,vol. 107, pp. 65- 71 ,(2010) , 10.3238/ARZTEBL.2010.0065
S Fucharoen, N Siritanaratkul, P Winichagoon, J Chowthaworn, W Siriboon, W Muangsup, S Chaicharoen, N Poolsup, B Chindavijak, P Pootrakul, A Piankijagum, AN Schechter, GP Rodgers, Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood. ,vol. 87, pp. 887- 892 ,(1996) , 10.1182/BLOOD.V87.3.887.BLOODJOURNAL873887
Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Sarah Gooding, Onima Chowdhury, David J Roberts, Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia Cochrane Database of Systematic Reviews. ,(2013) , 10.1002/14651858.CD004450.PUB3
S Davies, A Olujohungbe, None, Hydroxyurea for sickle cell disease Cochrane Database of Systematic Reviews. ,(2001) , 10.1002/14651858.CD002202
Paolo Rigano, Alice Pecoraro, Roberta Calzolari, Antonio Troia, Santina Acuto, Disma Renda, Gaetano Restivo Pantalone, Aurelio Maggio, Rosalba Di Marzo, Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology. ,vol. 151, pp. 509- 515 ,(2010) , 10.1111/J.1365-2141.2010.08397.X
Ali T. Taher, Khaled M. Musallam, Maria Domenica Cappellini, David J. Weatherall, Optimal management of β thalassaemia intermedia. British Journal of Haematology. ,vol. 152, pp. 512- 523 ,(2011) , 10.1111/J.1365-2141.2010.08486.X
Sherri A. Zimmerman, William H. Schultz, Jacqueline S. Davis, Chrisley V. Pickens, Nicole A. Mortier, Thad A. Howard, Russell E. Ware, Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease Blood. ,vol. 103, pp. 2039- 2045 ,(2004) , 10.1182/BLOOD-2003-07-2475
Vijay G. Sankaran, Tobias F. Menne, Jian Xu, Thomas E. Akie, Guillaume Lettre, Ben Van Handel, Hanna K. A. Mikkola, Joel N. Hirschhorn, Alan B. Cantor, Stuart H. Orkin, Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A Science. ,vol. 322, pp. 1839- 1842 ,(2008) , 10.1126/SCIENCE.1165409
John J. Strouse, Matthew M. Heeney, Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children Pediatric Blood & Cancer. ,vol. 59, pp. 365- 371 ,(2012) , 10.1002/PBC.24178
R. Origa, R. Galanello, T. Ganz, N. Giagu, L. Maccioni, G. Faa, E. Nemeth, Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. ,vol. 92, pp. 583- 588 ,(2007) , 10.3324/HAEMATOL.10842